The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Eagan-based Prime Therapeutics has been ordered to pay $10 million in damages after federal arbitration found it engaged in illegal price fixing with competitor Express Scripts to suppress drug reimbursement rates for HIV/AIDS treatments.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and Blue Shield Plans, was found guilty of engaging in horizontal price-fixing in collaboration with Express Scripts,

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent — for billions in profits, according to a report from the Federal Trade Commission,

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market. Meanwhile, the price patients pay for drugs has increased nearly 300% in the last 30 years, according to Peterson-KFF Health System Tracker.

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare Foundation (AHF) and independent pharmacies. | Prime Therapeutics, a PBM owned by Blue Cross plans,

Pharmacy benefit management giant Express Scripts unveiled several steps it's taking to boost transparency and mitigate high costs members may face.  | Pharmacy benefit management giant Express Scripts unveiled several steps it's taking to boost transparency and mitigate high costs members may face.

Express Scripts aims to ensure that patients directly benefit from its negotiations with drug manufacturers. The new approach will protect patients from paying inflated list prices for medications, instead providing them with the lower prices negotiated by the PBM, according to a Jan. 29 news release from the company.

Cigna Group CEO David Cordani said the company will make investments this year to improve patient and provider experiences with the insurer.

In his first confirmation hearing, Robert F. Kennedy Jr. tried to distance himself from his past statements on abortion and vaccines

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two